Bristol-Myers Squibb (NY:BMY)

SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Topics Economy Intellectual Property

February 26, 2026

Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics

February 25, 2026

In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total...

Bristol-Myers Squibb Co (NYSE:BMY) Offers a High Yield and Durable Dividend for Income Investors ↗

Topics Intellectual Property

February 18, 2026

Via Chartmill

Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity

February 24, 2026

EQNX::TICKER_START (NASDAQ:HELP),(CBOE:HELP),(NYSE:TAK),(NASDAQ:CMPS),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

3 Reasons to Avoid BMY and 1 Stock to Buy Instead

February 23, 2026

Over the past six months, Bristol-Myers Squibb has been a great trade, beating the S&P 500 by 22.8%. Its stock price has climbed to $61.33, representing a healthy 30.1% increase. This was partly due to...

Topics Stocks

Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference

February 23, 2026

European Commission Grants Marketing Authorization to Cytokinetics for Cardiac Drug MYQORZO

February 23, 2026

In a landmark decision for the cardiovascular treatment landscape, the European Commission (EC) officially granted marketing authorization to Cytokinetics, Inc. (Nasdaq: CYTK) on February 17, 2026, for...

Bristol Myers Squibb Co (NYSE:BMY) Beats Q4 2025 Earnings Estimates and Provides Strong 2026 Outlook ↗

Topics Intellectual Property

February 05, 2026

Via Chartmill

Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia

February 23, 2026

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth...

2 Large-Cap Stocks on Our Buy List and 1 That Underwhelm

February 22, 2026

The pharma industry's dreaded patent cliff is a key driver of the stock's decline.

Down 25%, Should You Buy the Dip on Bristol Myers Squibb? ↗

February 21, 2026

Yes, there are bargains out there for investors seeking income-paying stocks.

Topics Intellectual Property

2 Incredibly Cheap Dividend Stocks to Buy Now ↗

February 19, 2026

Any of these three pharmaceutical titans could move the needle in your portfolio.

Topics Intellectual Property

3 Stocks to Buy and Hold for 2026 and Beyond ↗

February 19, 2026

Cytokinetics Secures Triple Crown: EU Approval of MYQORZO Solidifies Global Reach in Cardiovascular Market

Topics Economy Intellectual Property

February 19, 2026

Cytokinetics, Inc. (Nasdaq: CYTK) has officially cleared its final major regulatory hurdle for its flagship heart failure drug, MYQORZO (aficamten), receiving marketing authorization from the European...

As of February 19, 2026, ImmunityBio, Inc. (NASDAQ: IBRX) stands at a pivotal crossroads between clinical ambition and commercial reality. Once a "story stock" fueled by the vision of its billionaire...

ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA

February 19, 2026

Via Finterra

Topics Lawsuit

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma

February 17, 2026

As the oncology community prepares to descend upon San Francisco for the 2026 ASCO Genitourinary (GU) Cancers Symposium from February 26–28, investors and clinicians alike are bracing for data that...

ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards

February 16, 2026

Bristol-Myers Squibb’s fourth quarter saw continued momentum in its growth portfolio, which management credited as the primary driver behind the company’s positive results. CEO Christopher Boerner...

Topics Intellectual Property

The 5 Most Interesting Analyst Questions From Bristol-Myers Squibb’s Q4 Earnings Call

February 12, 2026

As of February 11, 2026, Incyte Corporation (NASDAQ: INCY) finds itself at a pivotal crossroads. Known for over a decade as a one-drug powerhouse centered on the hematology blockbuster Jakafi, the...

Topics Earnings

Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss

February 11, 2026

Via Finterra

Topics Economy Intellectual Property

Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse

February 10, 2026

Date: February 10, 2026 Introduction For years, Gilead Sciences, Inc. (Nasdaq: GILD) was characterized by investors as a "value trap"—a cash-rich biopharma giant that had lost its way after the...

Via Finterra

Topics Economy Intellectual Property

The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff

February 06, 2026

The life sciences sector has entered 2026 in the midst of a historic transformation, as deal volume and value surged by a staggering 82% over the past year. This "Great Rebound," fueled by a...

As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a...

Topics Artificial Intelligence Economy Intellectual Property

Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model

February 06, 2026

Via Finterra

Topics ETFs Economy Initial Public Offering

BMY Q4 Deep Dive: Growth Portfolio Offsets Legacy Pressure, Pipeline Readouts in Focus

February 06, 2026

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 1.4% year on year to $12.5 billion. The company’s full-year revenue...

At the end of last year, the company did particularly well with its lineup of newer medications.

Why Bristol Myers Squibb Stock Topped the Market Today ↗

February 05, 2026

Bristol Myers (BMY) Q4 2025 Earnings Transcript

Bristol Myers (BMY) Q4 2025 Earnings Transcript ↗

February 05, 2026

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q4 CY2025, with sales up 1.4% year on year to $12.5 billion. The company’s full-year revenue guidance...

Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q4 CY2025

February 05, 2026

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025

February 05, 2026

Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi

February 04, 2026